Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

Published Medical Literature

Is Higher Body Mass Index a Risk Factor for Multiple Myeloma?
Potential of Folate-Targeted Therapies for Multiple Myeloma
Updated ASCO Guideline for Use of Bone-Modifying Agents in Multiple Myeloma
Is DCEP Chemotherapy a Viable Bridge to Definitive Therapy in Resistant Myeloma?
Screening Strategies in Individuals at Risk of Developing Multiple Myeloma
Are Recipients of Hematopoietic Cell Transplantation at Risk for Cognitive Decline?
Denosumab Versus Zoledronic Acid for Treating Myeloma With Bone Disease
Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma
ASPIRE Trial: Triplet Therapy in Relapsed or Refractory Multiple Myeloma
High-Dose Therapy Followed by Autologous Stem Cell Transplant for Multiple Myeloma
Considering Newer Agents in Managing Relapse in Resistant Myeloma
BCMA as a Therapeutic Target and Biomarker in Multiple Myeloma
Clinical Practice Update on Bone-Modifying Agents in Patients With Multiple Myeloma
Infection Prevention in Patients With Multiple Myeloma
Early Research Studies May Advance the Treatment of Multiple Myeloma
Carfilzomib and Cardiovascular Adverse Events in Patients With Multiple Myeloma
Novel Antibody Clone for Targeting Multiple Myeloma Cancer Cells
Survival and CRP Levels Prior to Transplantation in Patients With Multiple Myeloma
Novel Three-Part Treatment Sequence in High-Risk Multiple Myeloma
What Role, If Any, Does Obesity Play in MGUS and Multiple Myeloma?
Cost-Effectiveness Comparisons of Treatments for Heavily Pretreated Multiple Myeloma
Differences in Genetic Mutations in Blacks and Whites With Multiple Myeloma
Venetoclax Combination Therapy for Relapsed or Refractory Multiple Myeloma
Can Type of Myeloma Influence Response to Monoclonal Antibodies?
Multiple Myeloma Precancerous Disease and African Americans
Gene Signature in Predicting Response to Immunomodulatory Derivatives in Myeloma
Protein Kinases CK1-alpha and CK2 in Pathogenesis of Multiple Myeloma
Carfilzomib Versus Bortezomib in Relapsed or Refractory Multiple Myeloma
Prognostic Immune Biomarker in Newly Diagnosed Multiple Myeloma
Lenalidomide Maintenance After Transplantation in Multiple Myeloma
MRI Versus PET-CT in Symptomatic Patients With Multiple Myeloma
Bendamustine, Prednisone, and Bortezomib Treatment for Light Chain Multiple Myeloma
Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma
Treatment Tolerability in Patients With Relapsed or Refractory Multiple Myeloma
Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma
Induction and Maintenance Therapies With Bortezomib in Myeloma
Prognostic Impact of MRD-Negative Status in Multiple Myeloma
Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study
Combination Treatment With or Without Transplantation in Multiple Myeloma